Microbot Medical Inc. (NASDAQ: MBOT) appointed Alon Tamir as Vice President of Sales for Europe, the Middle East, and Asia. The medical device company plans to expand internationally while maintaining focus on its U.S. market operations.

Tamir will develop sales strategies, distribution networks, and strategic partnerships across the EMEA region for the company's LIBERTY Endovascular Robotic System. The company received FDA clearance for its technology in September 2025 and expects to obtain CE mark approval by the end of 2026.

Microbot Medical completed a limited market release followed by a full market release in the United States. The company stated that Europe represents approximately 2.3 million peripheral endovascular procedures annually, comparable to the U.S. market volume.

"With over two decades of experience across the diagnostic, interventional, and robotics space, I've rarely seen a technology so well positioned — FDA-cleared, already commercially launched, and now advancing toward CE mark approval," Tamir said.

The company plans to leverage either its FDA clearance or the anticipated CE mark to enter international markets. Microbot Medical stated it will pursue opportunities in countries where FDA clearance may accelerate market entry.

"As we continue to focus on the U.S. market, and build on the growing adoption of the LIBERTY System, especially after entering the Full Market Release phase, it is equally important that we establish a robust commercial readiness strategy in certain international markets," said Harel Gadot, Chairman, CEO and President.

The LIBERTY system is described as a single-use, remotely operated robotic solution for endovascular procedures. Information is based on a company press release.